Conjugate of α-amylase and symmetric dimethylarginine, and application thereof

A conjugate of α-amylase and SDMA with a 10 to 17-atom linker using Sulfo-GMBS overcomes the limitations of harmful crosslinking agents, achieving high S/N ratio quantification of SDMA for renal and cardiovascular disease detection.

WO2025205769A1 Publication Date: 2025-10-02FUJIFILM CORP
6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2025/011736
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-26
Filing Date
2025-03-25
Publication Date
2025-10-02

AI Technical Summary

Technical Problem

Existing SDMA quantification methods face challenges in achieving a high signal-to-noise (S/N) ratio while using safe and inexpensive materials, as conventional crosslinking agents generate harmful substances and have limited tolerance for the number of atoms in the crosslinking group.

Method used

A conjugate of α-amylase and symmetric dimethylarginine (SDMA) is formed using a linker with 10 to 17 atoms, utilizing a safe and commercially available crosslinking agent like Sulfo-GMBS, which does not generate harmful hydrogen halides, enabling high S/N ratio quantification of SDMA.

Benefits of technology

The conjugate allows for safe, inexpensive, and efficient quantification of SDMA with a high S/N ratio, suitable for early detection of renal and cardiovascular diseases, particularly in veterinary medicine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention addresses the problem of providing: a conjugate of α-amylase and symmetrical dimethylarginine that makes it possible to quantify SDMA at a high S / N ratio; a reagent, a kit, and a test piece for measurement which contain the conjugate and which are for measuring symmetrical dimethylarginine in a biological sample; and a method for measuring free symmetric dimethylarginine using the conjugate. According to the present invention, provided is a conjugate of α-amylase and symmetric dimethylarginine, wherein the α-amylase is conjugated to symmetric dimethylarginine via a linker having a cross-linking group having 10-17 atoms.
Need to check novelty before this filing date? Find Prior Art